Serotonin syndrome and drug combinations: Focus on MAOI and RIMA

European Archives of Psychiatry and Clinical Neuroscience

Volumn 247, Issue 3, 1997, Pages 113-119

  Hilton, S E ^a   Maradit, H ^a   Moller H J ^b  

^a Depts Drug Regulatory Aff Drug S   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antidepressants; Moclobemide; RIMA; Safety; Serotonin syndrome

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; SEROTONIN;

AUTONOMIC NERVOUS SYSTEM FUNCTION; BEHAVIOR; BRAIN STEM; COGNITION; HUMAN; HYPOTHESIS; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEROTONIN SYNDROME;

EID: 0030994139     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033064     Document Type: Review

References (49)

1. Bakish D, Hooper CL, West DL, Miller C, Blanchard A et al. (1995) Moclobemide and specific serotonin re-uplake inhibitor combination treatment of resistant anxiety and depressive disorders.Hum Psychopharmacol 10: 105-109
2. Benfield P, Heel RC, Lewis SP (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 481-508
3. Beumont G (1973) Drug interaction with clomipramine (Anafranil). J Int Med Res: 480-484
4. Brachfield J, Wirtshafter A, Wolfe S (1963) Imipramine-trancylcypramine incompatibility. J Am Med Assoc 186: 1172-1173
5. Brown TM, Skop BP, Mareth TR (1996) Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 30(5): 527-533
6. Brownlee G, Williams GW (1963) Potentiation of amphetamine and pethidine by monoamine oxidase inhibitors. Lancet 1: 669
7. Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W (1989) Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry Suppl 6: 84-88
8. Coplan JD, Gorman JM (1993) Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 150: 837
9. Da Prada M, Kettler R, Keller HH, Burkard WP (1990) Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr Scand Suppl 360: 103-105
10. Dingemanse J (1993) An update of recent moclobemide interaction data. Int Clin Psychopharmacol 7: 167-180
11. Ebert D, Albert R, May A, Stosiek I, Kaschka W (1995) Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology (Berl) 119(3): 342-344
12. Grahame-Smith DG (1971) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18: 1053-1066
13. Green AR (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 119: 247-260
14. Green AR, Grahame-Smith DG (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature 260: 487-491
15. Green AR, Youdim MBH (1975) Effects of monoamine inhibition by clorgyline, deprenil or tranylcypramine on 5-HT concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 55: 415-422
16. Green R, Grahame-Smith DG (1974) The role of brain dopamine in the hyperactivity syndrome produced by increased 5-HT synthesis in rats. Neuropharmacology 13: 949-959
17. Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, Martin JR, Moreau J, Richards JG, Schaffner R et al. (1993) Pharmacology of moclobemide. Clin Neuropharmacol 16 (Suppl 2): 8-18
18. Hetzel W (1992) Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology Suppl 106: 127-129
19. Holford NH, Guentert TW, Dingemanse J, Banken L (1994) Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmucol 37(5): 433-439
20. Hoyer D, Clarke DE, Fozard JR et al. (1994) International union of pharmacology classification of receptors for 5-hyroxytryptamine (serotonin). Pharmacol Rev 46(2): 157-203
21. Iwersen S, Schmoldt A (1996) Three suicide attempts with moclobemide. J Toxicol Clin Toxicol 34: 223-225
22. Jermain DM, Hughes PL, Follender AB (1992) Potential fluoxetine-selegeline interaction. Ann Pharmacother 26: 1300
23. Joffe RT, Bakish D (1994) Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 55(1): 24-25
24. Judd FK, Mijch AM, Cockram A, Norman TR (1994) Isoniazid and antidepressants: Is there a cause for concern? Int Clin Psychopharmacol 9: 123-125
25. Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by mocobemide and RO 166491. Arch Pharmacol 335: 12-20
26. Kuisma MJ (1995) Fatal serotonin syndrome with trismus. Ann Emerg Med 26: 108
27. Lejoyeux M, Léon E, Adès J (1995) The serotonin syndrome. Focus Depression Anxiety 6(1): 4-11
28. Lejoyeux M, Rouillon F, Adès J (1993) Prospective evaluation of the serotonin syndrome in depressed patients treated with clomipramine. Acta Psychiatr Scand 88: 369-71
29. Loveless AH, Maxwell DR (1969) A comparison of the effect of imipramine, trimipramine and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 36: 470-480
30. Lucki I, Frazer A (1982) Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants. Psychopharmacology 77: 10511
31. Mills KC (1995) Serotonin syndrome. Am Fam Phys 52(5): 1475-1482
32. Mitchell RS (1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 42: 417-424
33. Möller HJ (1991) Fluoxetine: safety and side effects in practice. In: Freeman H (ed) International congress and symposium series 183. Royal Society of Medicine Services, London, pp 61-66
34. Myrenfors PG, Eriksson T, Sandstedt CS, Sjobert G (1993) Moclobemide overdose. J Intern Med 233: 113-115
35. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: 1419
36. Nymark M, Nielsen J (1963) Reactions due to the combination of monoamine oxidase inhibitors with thymoleptics. Lancet 2: 524-525
37. Ortmann R (1984) The 5-HT syndrome in rats as tool for the screening of psychoactive drugs. Drugs Dev Res 4: 593-606
38. Papp C, Benaim S (1958) Toxic effects of iproniazid in a patient with angina. Br Med J 1070-1072
39. Pedersen V, Nielsen IM (1975) Hyperthermia in rabbits caused by interaction between MAOIs, antiparkinsonian drugs, and neuroleptics. Lancet 1: 409
40. Power BNM, Pinder M, Hackett LP, Ilett KF (1995) Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intensive Care 23: 499-502
41. Sinclair JG (1973) Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits. J Pharm Pharmacol 25: 803-808
42. Singh H (1961) Atropine-like poisoning due to tranquillizing agents. Am J Psychiatry 117: 360-361
43. Spigset O, Mjorndal T, Lovenheim O (1993) Serotonin syndrome caused by a moclobemide-clomipramine interaction. Br Med J 306: 248
44. Sporer K (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Safety 13(2): 94-104
45. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705-713
46. Suchowersky O, Vries J de (1990) Interaction of fluoxetine and selegiline. Can J Psychiatry 35: 571-572
47. Suchowersky O, Vries J de (1990) Possible interactions between Deprenyl and Prozac. Can J Neurol Sci 17: 352-353
48. Volz HP, Gleiter CH, Waldmeier PC et al. (1996) Brofaromine: a review of its pharmacological properties and therapeutic use. 103: 217-245
49. Wallnoefer A, Guentert TW, Eckernas SA, Dingemanse J (1995) Moclobemide and fluvoxamine co-administration: a prospective study in healthy volunteers to investigate the potential development of the serotonin syndrome. Hum Psychopharmacol 10: 25-31